December 6, 2024

Leukemia Screening: Types of Tests and Screening Procedures Available

Introduction

Leukemia is a type of cancer that starts in the bone marrow and results in an abnormal production of blood cells. If left undetected and untreated, leukemia can spread to other parts of the body through the bloodstream. Early detection through regular screening plays a crucial role in the effective treatment and management of leukemia. This article discusses the importance of leukemia screening and the various screening methods available to catch this blood cancer in its early stages.

What is Leukemia?

Leukemia is a cancer of the blood cells that develops in the bone marrow, which is the soft inner part of certain bones that produces blood cells. There are four main types of leukemia – acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), and chronic lymphocytic leukemia (CLL). Leukemia occurs due to mutations in the DNA of bone marrow stem cells and white blood cells, leading to the overproduction of abnormal white blood cells. These abnormal white blood cells are not fully developed and functional and accumulate in the bone marrow and blood, preventing the production of normal red blood cells, platelets, and other necessary blood components.

Symptoms of Leukemia

Early detection of leukemia is crucial for effective treatment. The common symptoms of leukemia include fatigue, weakness, fever, pale skin, frequent infections, easy bleeding or bruising, swollen lymph nodes, enlarged liver or spleen, and bone or joint pain. However, these symptoms are often vague and flu-like in nature, making early diagnosis difficult without proper screening. The symptoms may often be ignored or confused with common infections at the initial stages. Regular screening helps catch any abnormal blood counts or signs of leukemia early on before major symptoms develop.

Importance of Early Detection

Screening allows catching leukemia in its early or asymptomatic stages, known as early-stage or incidental leukemia. Early detection typically results in a better prognosis and higher survival rates. Treatment is often more effective when the disease is detected at a localized early stage. Delayed diagnosis often means that the leukemia has already progressed to an advanced stage with worse treatment outcomes. Screening blood cell counts and blood smears can spot subtle abnormalities indicating pre-leukemic conditions or very early leukemia that may not have resulted in severe symptoms yet. Early intervention prevents further disease advancement and associated complications.

Who Should Get Screened?

The following high-risk groups are recommended to get routine screening blood tests done to detect any sign of leukemia at the earliest:

– Individuals who have been exposed to radiation or certain chemicals that are known leukemia causes.

– People with certain genetic conditions like Down syndrome that increase the risk of developing leukemia.

– Those who have had prior chemotherapy or radiation treatment for other cancers.

– Individuals who have taken immunosuppressant drugs after organ transplantation.

– Family history of blood cancers like leukemia in a parent, sibling, or child.

– Patients with certain blood disorders like myelodysplastic syndrome that could progress to develop leukemia.

– Older adults, as the risk of developing leukemia increases with age.

Screening Tests for Leukemia

The common screening tests done to detect leukemia early include:

– Complete blood count (CBC): This simple blood test measures red blood cell count, white blood cell count, hemoglobin level, hematocrit, platelet count, and examines the size and shape of blood cells under the microscope. It can spot abnormalities indicating early leukemia.

– Blood smears: Thin blood films are prepared from a blood sample and examined under a microscope for any immature or abnormal white blood cells.

– Bone marrow biopsy/aspirate: A small sample of liquid bone marrow or solid bone tissue is extracted from the hip bone using a specialized needle. It is examined for malignant blasts or abnormal cells.

– Cytochemical/immunophenotyping tests: These specialized tests analyze cell characteristics and blood cell protein markers to identify specific leukemia cell types.

– Cytogenetic tests: These identify any genetic mutations or chromosomal abnormalities in blood or bone marrow cells that are characteristic of certain types of leukemia.

– Molecular genetic tests: Advanced tests look for specific genetic alterations or mutations in leukemia cells through techniques like fluorescent in situ hybridization (FISH), polymerase chain reaction (PCR), and next-generation sequencing.

Taking Action with an Abnormal Screening Test

If any screening test detects an abnormal white blood cell count, unusual cells, or suspicious mutations, further diagnostic tests are required to confirm or rule out a leukemia diagnosis. A bone marrow biopsy may be needed in such cases. Early detection also helps design an optimal treatment approach depending on the leukemia type and stage. Close monitoring of high-risk groups can help doctors catch any recurrence early as well. Changing lifestyle habits like avoiding tobacco use, limiting alcohol, and maintaining a healthy weight and diet also supports optimal screening outcomes.

Conclusion

Leukemia screening helps achieve early detection which significantly improves survival rates and therapeutic options. Regular screening of high-risk groups through simple yet effective blood tests can ensure any concerning changes are caught in the very initial asymptomatic phase. Early diagnosis opens up opportunities for less intensive treatment options, better management of the disease, and makes long-term remission highly likely. Wider community awareness about leukemia screening is key to enhancing early detection rates and ultimately reducing leukemia mortality.

*Note:

  1. Source: Coherent Market Insights, Public sources, Desk research
  2. We have leveraged AI tools to mine information and compile it
Money Singh
+ posts

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc. 

Money Singh

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc. 

View all posts by Money Singh →